{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:17:30Z","timestamp":1783707450980,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.eururo.2023.05.014","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:47:05Z","timestamp":1686962825000},"page":"302-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel"],"prefix":"10.1016","volume":"84","author":[{"given":"Fawzy","family":"Farag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios I.","family":"Sakalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serenella Monagas","family":"Arteaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00e9ha","family":"Sihra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markos","family":"Karavitakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Arlandis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"B\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanny","family":"Cobussen-Boekhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Costantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"de Heide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Peyronnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Ph\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Lynne","family":"van Poelgeest-Pomfret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine W.L.","family":"van den Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huub","family":"van der Vaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Carmela Lapitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Imran Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun K.","family":"Nambiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2023.05.014_b0005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/nau.22609","article-title":"Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013","volume":"33","author":"Drake","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2023.05.014_b0010","doi-asserted-by":"crossref","unstructured":"Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306\u201314; discussion 1314\u20135.","DOI":"10.1016\/j.eururo.2006.09.019"},{"key":"10.1016\/j.eururo.2023.05.014_b0015","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/luts.12185","article-title":"Prevalence and risk factors of urinary incontinence and overactive bladder in Japanese women","volume":"10","author":"Ninomiya","year":"2018","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.eururo.2023.05.014_b0020","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.eururo.2013.08.031","article-title":"Global prevalence and economic burden of urgency urinary incontinence: a systematic review","volume":"65","author":"Milsom","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0025","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.eururo.2005.04.026","article-title":"Prevalence of the overactive bladder syndrome by applying the international continence society definition","volume":"48","author":"Temml","year":"2005","journal-title":"Eur Urol"},{"issue":"6 Suppl 1","key":"10.1016\/j.eururo.2023.05.014_b0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.urology.2004.10.047","article-title":"Defining overactive bladder: epidemiology and burden of disease","volume":"64","author":"Tubaro","year":"2004","journal-title":"Urology"},{"issue":"Suppl 3","key":"10.1016\/j.eururo.2023.05.014_b0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1464-410X.2009.08371.x","article-title":"The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression","volume":"103","author":"Coyne","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.05.014_b0040","first-page":"145","article-title":"Effectiveness of percutaneous tibial nerve stimulation in the treatment of overactive bladder syndrome","volume":"9","author":"de Wall","year":"2017","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0045","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2023.05.014_b0050","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2017.08.016","article-title":"Key steps in conducting systematic reviews for underpinning clinical practice guidelines: methodology of the European Association of Urology","volume":"73","author":"Knoll","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0055","unstructured":"Deeks JJ, Higgins JPT, Altman DG; on behalf of the Cochrane Statistical Methods Group, editors. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Chapter 10: Analysing data and undertaking meta-analyses. Cochrane; 2021. http:\/\/www.training.cochrane.org\/handbook."},{"key":"10.1016\/j.eururo.2023.05.014_b0060","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1464-410X.2007.07162.x","article-title":"A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome","volume":"100","author":"Robinson","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.05.014_b0065","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1185\/03007990903103279","article-title":"Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence","volume":"25","author":"Rogers","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.eururo.2023.05.014_b0070","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00192-008-0688-6","article-title":"Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women","volume":"19","author":"Rogers","year":"2008","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.eururo.2023.05.014_b0075","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1590\/s1677-5538.ibju.2016.0611","article-title":"Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months","volume":"44","author":"Vecchioli-Scaldazza","year":"2018","journal-title":"International Braz J Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0080","first-page":"208","article-title":"Role of percutaneous posterior tibial nerve stimulation either alone or combined with an anticholinergic agent in treating patients with overactive bladder","volume":"41","author":"K\u0131z\u0131lyel","year":"2015","journal-title":"Turk Urol Dergisi"},{"key":"10.1016\/j.eururo.2023.05.014_b0085","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/luts.12169","article-title":"Low-dose desmopressin and tolterodine combination therapy for treating nocturia in women with overactive bladder: a double-blind, randomized, controlled study","volume":"10","author":"Rovner","year":"2018","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.eururo.2023.05.014_b0090","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/0269215510385481","article-title":"Comparison of different treatment protocols in the treatment of idiopathic detrusor overactivity: a randomized controlled trial","volume":"25","author":"Kaya","year":"2011","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.eururo.2023.05.014_b0095","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/iju.13231","article-title":"Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: a randomized controlled trial (COMFORT study)","volume":"23","author":"Otsuka","year":"2016","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0100","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/GME.0000000000000574","article-title":"Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women\u2014a multicenter, randomized, open-label, controlled comparison study","volume":"23","author":"Jiang","year":"2016","journal-title":"Menopause"},{"key":"10.1016\/j.eururo.2023.05.014_b0105","first-page":"243","article-title":"The efficacy and safety of solifenacin in patients with overactive bladder syndrome","volume":"36","author":"Oreskovic","year":"2012","journal-title":"Coll Antropol"},{"key":"10.1016\/j.eururo.2023.05.014_b0110","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejogrb.2015.09.020","article-title":"Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial","volume":"196","author":"Manr\u00edquez","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.eururo.2023.05.014_b0115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/nau.20928","article-title":"Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder","volume":"30","author":"Marencak","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2023.05.014_b0120","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.cct.2014.04.009","article-title":"Web-based trial to evaluate the efficacy and safety of tolterodine ER 4mg in participants with overactive bladder: REMOTE trial","volume":"38","author":"Orri","year":"2014","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.eururo.2023.05.014_b0125","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3109\/09513591003649815","article-title":"The outcome of adding peripheral neuromodulation (Stoller afferent neuro-stimulation) to anti-muscarinic therapy in women with severe overactive bladder","volume":"26","author":"Sancaktar","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.eururo.2023.05.014_b0130","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejogrb.2015.05.014","article-title":"Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial","volume":"191","author":"Preyer","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.eururo.2023.05.014_b0135","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000445808","article-title":"Comparison of therapeutic efficacy and urodynamic findings of solifenacin succinate versus mirabegron in women with overactive bladder syndrome: results of a randomized controlled study","volume":"97","author":"Vecchioli Scaldazza","year":"2016","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2023.05.014_b0140","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/nau.20583","article-title":"Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome","volume":"28","author":"Tseng","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2023.05.014_b0145","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.urology.2006.05.038","article-title":"Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial","volume":"68","author":"Wang","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.05.014_b0150","doi-asserted-by":"crossref","first-page":"168.e1","DOI":"10.1016\/j.ajog.2011.08.005","article-title":"Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome","volume":"206","author":"Sand","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.eururo.2023.05.014_b0155","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1159\/000358202","article-title":"Acupuncture versus solifenacin for treatment of overactive bladder and its correlation with urine nerve growth factor levels: a randomized, placebo-controlled clinical trial","volume":"93","author":"Aydo\u0287mu\u015f","year":"2014","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2023.05.014_b0160","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/ijcp.12705","article-title":"Interventions do not enhance medication persistence and compliance in patients with overactive bladder: a 24 weeks, randomised, open-label, multi-center trial","volume":"69","author":"Sung","year":"2015","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.eururo.2023.05.014_b0165","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bju.12174","article-title":"Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder","volume":"112","author":"Ginsberg","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.05.014_b0170","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/nau.23361","article-title":"Transcutaneous posterior tibial nerve electrostimulation with low dose trospium chloride: could it be used as a second line treatment of overactive bladder in females","volume":"37","author":"Abulseoud","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2023.05.014_b0175","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/nau.23050","article-title":"Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: a randomized crossover study (the MICRO study)","volume":"36","author":"Torimoto","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2023.05.014_b0180","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/2053369116633017","article-title":"The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women","volume":"22","author":"Chughtai","year":"2016","journal-title":"Post Reprod Health"},{"key":"10.1016\/j.eururo.2023.05.014_b0185","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12894-016-0167-1","article-title":"The combination of herbal medicine Weng-li-tong with tolterodine may be better than tolterodine alone in the treatment of overactive bladder in women: a randomized placebo-controlled prospective trial","volume":"16","author":"Xiao","year":"2016","journal-title":"BMC Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0190","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00345-013-1112-5","article-title":"Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women with overactive bladder syndrome","volume":"32","author":"Souto","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0195","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/iju.14608","article-title":"Effect of oxybutynin patch versus mirabegron on nocturia-related quality of life in female overactive bladder patients: a multicenter randomized trial","volume":"28","author":"Suzuki","year":"2021","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0200","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1080\/13548506.2021.1916962","article-title":"The effect of a counseling and training program on the treatment of women with overactive bladder","volume":"27","author":"Cayir","year":"2022","journal-title":"Psychol Health Med"},{"key":"10.1016\/j.eururo.2023.05.014_b0205","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.3346\/jkms.2006.21.6.1060","article-title":"Effects of bladder training and\/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study","volume":"21","author":"Song","year":"2006","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.eururo.2023.05.014_b0210","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1701-2163(15)31049-5","article-title":"Efficacy of botulinum toxin A intradetrusor injections for non-neurogenic urinary urge incontinence: a randomized double-blind controlled trial","volume":"35","author":"Jabs","year":"2013","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.eururo.2023.05.014_b0215","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1208872","article-title":"Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence","volume":"367","author":"Visco","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.05.014_b0220","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.juro.2017.01.069","article-title":"The efficacy and safety of onabotulinumtoxinA or solifenacin compared with placebo in solifenacin na\u00efve patients with refractory overactive bladder: results from a multicenter, randomized, double-blind phase 3b trial","volume":"198","author":"Herschorn","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0225","doi-asserted-by":"crossref","DOI":"10.1002\/nau.21021","article-title":"Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder","volume":"30","author":"Rovner","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2023.05.014_b0230","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0235","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","article-title":"Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder","volume":"181","author":"Flynn","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0240","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3109\/21681805.2015.1121406","article-title":"Intravesical instillation of onabotulinum toxin A embedded in inert hydrogel in the treatment of idiopathic overactive bladder: a double-blind randomized pilot study","volume":"50","author":"Krhut","year":"2016","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0245","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.eururo.2011.12.056","article-title":"Botulinum toxin A versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX Study)","volume":"62","author":"Tincello","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0250","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.juro.2008.03.028","article-title":"Refractory idiopathic urge urinary incontinence and botulinum A injection","volume":"180","author":"Brubaker","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0255","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0260","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0265","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/SPV.0000000000000914","article-title":"early and consistent improvements in urinary symptoms and quality of life with onabotulinumtoxinA in patients with overactive bladder and urinary incontinence: results from a randomized, placebo-controlled, phase IV clinical trial","volume":"27","author":"McCammon","year":"2021","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1016\/j.eururo.2023.05.014_b0270","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/iju.14176","article-title":"OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis)","volume":"27","author":"Yokoyama","year":"2020","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0275","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1742-1241.2011.02663.x","article-title":"The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial","volume":"65","author":"Dowson","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.eururo.2023.05.014_b0280","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.eururo.2011.10.028","article-title":"Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study","volume":"61","author":"Denys","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0285","unstructured":"Harding CK, Lapitan M, Arlandis S, et al. Non-neurogenic female LUTS guideline. EAU guidelines. Presented at the EAU Annual Congress Amsterdam 2022. Arnhem, the Netherlands: EAU Guidelines Office; 2022."},{"key":"10.1016\/j.eururo.2023.05.014_b0290","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.eururo.2023.05.014_b0295","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.eururo.2018.02.011","article-title":"Two-year outcomes of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: a randomized trial","volume":"74","author":"Amundsen","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0300","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/nau.22544","article-title":"Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder","volume":"34","author":"Siegel","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2023.05.014_b0305","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/SPV.0000000000000457","article-title":"Prospective randomized feasibility study assessing the effect of cyclic sacral neuromodulation on urinary urge incontinence in women","volume":"24","author":"Siegel","year":"2018","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1016\/j.eururo.2023.05.014_b0310","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/SPV.0000000000000188","article-title":"Prospective randomized crossover trial comparing continuous and cyclic stimulation in InterStim therapy","volume":"21","author":"Markle Price","year":"2015","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1016\/j.eururo.2023.05.014_b0315","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.eururo.2013.11.010","article-title":"Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison","volume":"65","author":"Maman","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.05.014_b0320","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.euf.2021.08.011","article-title":"Choosing the most efficacious and safe oral treatment for idiopathic overactive bladder: a systematic review and network meta-analysis","volume":"8","author":"Mostafaei","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2023.05.014_b0325","first-page":"29","article-title":"Traitement de I'hyperactivit\u00e9 v\u00e9sicale r\u00e9fractaire non neurog\u00e8ne par la toxine botulique. Revue de la literature [Botulinum toxin injection for refractory non-neurogenic overactive bladder. Systematic review]","volume":"36","author":"Henriet","year":"2015","journal-title":"Rev Med Brux"},{"key":"10.1016\/j.eururo.2023.05.014_b0330","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/bju.13945","article-title":"Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis","volume":"120","author":"Drake","year":"2017","journal-title":"BJU Int"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283823028191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283823028191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:13:30Z","timestamp":1759583610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283823028191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0302283823028191"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2023.05.014","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2023.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}